MedTrace Logo

Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation

NCT01147380 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-03-10

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate feasibility and safety of the adoptive transfer of activated natural killer (NK) cells extracted from cadaveric donor liver graft perfusate for liver transplant recipients with hepatocellular carcinoma (HCC)

Conditions

Interventions

BIOLOGICAL

Liver NK cell inoculation

Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.

Sponsors & Collaborators

  • Florida Department of Health

    collaborator OTHER_GOV

  • Seigo Nishida

    lead OTHER

Principal Investigators

  • Seigo Nishida, MD PhD · Department of Surgery, University of Miami

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01147380 on ClinicalTrials.gov